Individuals with the following non-invasive cancers are eligible: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin
Has any other histologic type of skin cancer other than invasive squamous cell carcinoma as the primary disease under study, eg, basal cell carcinoma that has not been definitively treated with surgery or radiation, Bowen's disease, Merkel cell carcinoma (MCC), melanoma.
History of other prior malignancy, except squamous cell carcinoma of the cervix or anus, superficial basal cell or squamous cell skin cancer, or other malignancy curatively treated more than 5 years ago before enrollment
Patient has a history of new diagnosis or treatment of cancer other than malignant glioma within five years prior to start of the study, except for basal cell carcinoma or squamous cell carcinoma.
Another malignancy excluding basal cell skin cancer
Evidence of any other cancer within the past 5 years and < 50% probability of a 5 year survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell cancer of the skin is allowed).
Active malignancy (excluding localized squamous cell or basal cell carcinoma of the skin)
Participants who had curatively treated invasive malignancies for which all treatments ended within 1 year prior to the study (with the exception of basal cell or squamous cell carcinoma of the skin)
Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin
Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin
Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ that is unlikely to progress in two years
Basal cell carcinoma of the skin, medulloblastoma, small-cell lung cancer, or hematologic malignancies
Participant with a history of a second cancer diagnosis or reoccurrence < 5 years from study entry with the exception of a history of squamous or basal cell carcinoma of the skin < 5 years from study entry will not be excluded from this study
Any other invasive cancer in the past 5 years, except basal cell skin
Prior history of malignancy other than HCC, dermatologic basal cell or squamous cell carcinoma
Any other malignancy diagnosed within 1 year of study entry (except basal or squamous cell skin cancers or noninvasive cancer of the cervix) is excluded
Subjects diagnosed with another cancer in the past 3 years; excluding basal cell carcinoma or squamous cell carcinoma, of skin which were completely cured by resection
Evidence of any other cancer within the past 5 years and < 50% probability of a 5 year survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell cancer of the skin is allowed).
Concurrent malignancy other than Kaposi sarcoma, resectable squamous cell or basal cell skin cancer, or T1 anal cancer amenable to surgical resection
Evidence of any other cancer within the past 5 years and < 50% probability of a 5 year survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell cancer of the skin is allowed)
Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator’s opinion will shorten survival to less than 1 year
Previously diagnosed malignancy excluding basal or squamous cell carcinoma of the skin (unless disease-free for 5 years or more)
History of another malignancy within 5-years of date of except history of (h/o) basal cell or squamous cell carcinoma of skin or polycythemia vera or essential thrombocythemia
Noninvasive basal cell and squamous cell skin carcinoma
Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
No active second malignancy with the exception of basal or squamous cell carcinoma of the skin
Skin cancer other than actinic keratosis, basal cell carcinoma, and squamous cell carcinoma in situ in the field of RT
Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator’s opinion will shorten survival to less than 1 year.
Diagnosis or recurrence of invasive cancer other than the present cancer within 3 years (except basal or squamous cell carcinoma of the skin that has been definitively treated).
The subject must not have had diagnosis, detection, or treatment of another type of cancer =< 2 years prior to randomization (except basal or squamous cell carcinoma of the skin that has been definitively treated); questions regarding the inclusion of individual subjects should be directed to the principal investigators, Dr. Isaacs and Dr. Pishvaian
Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator’s opinion will shorten survival to less than 1 year.
History of prior malignancy that has not been in remission for >5 years, with the exception of basal cell or squamous cell carcinoma.
Evidence of metastatic disease or other malignancy (except squamous or basal cell skin cancers)
Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
Patients with second malignancies in addition to their lymphoma are not eligible if the second malignancy has required treatment (including maintenance therapy) within the past 4 years or is not in complete remission; there are two exceptions to this criterion: successfully treated non-metastatic basal cell or squamous cell skin carcinoma
Prior history of malignancy in the past 3 years with the exception of basal cell and squamous cell carcinoma of the skin; other malignancies that are considered to have a low potential to progress may be enrolled at discretion of principal investigator (PI)
Concomitant malignancies except cutaneous squamous cell carcinoma or basal cell carcinoma
Patients with other active malignancies are ineligible for this study, other than superficial localized skin cancer (basal or squamous cell carcinoma)
Patients must not have a different active malignancy, except for skin basal cell carcinoma, skin squamous cell carcinoma and cervical intraepithelial neoplasia
History of other malignancy within the previous 3 years, except basal cell or squamous cell carcinoma, or non-muscle invasive bladder cancer.
Prior history of malignancy in the past 3 years with the exception of basal cell and squamous cell carcinoma of the skin; other malignancies that are considered to have a low potential to progress may be enrolled at discretion of principal investigator (PI)
Patients with an active second invasive malignancy, other than basal cell carcinoma of the skin.
Concurrent, active malignancies in addition to those being studied (other than cutaneous squamous cell carcinoma or basal cell carcinoma)
Patients with second malignancies in addition to their B-cell malignancy are not eligible if the second malignancy has required treatment (including maintenance therapy) within the past 4 years or is not in complete remission; there are two exceptions to this criterion: successfully treated non-metastatic basal cell or squamous cell skin carcinoma
No evidence (within 5 years) of prior malignancies (except successfully treated basal cell or squamous cell carcinoma of the skin)
No prior history of keratoacanthoma (well differentiated squamous cell skin cancer variant, often centrally ulcerated); history of basal cell cancer is allowed
Patients may have had a prior diagnosis of cancer if it has been > 3 years since their last treatment (with the exception of squamous cell carcinoma or basal cell carcinoma of the skin or cervical intraepithelial neoplasia)
Patients with a history of any active malignancy requiring on-going treatment, except basal cell carcinoma or squamous cell carcinoma of the skin
Concurrent active or measurable malignancies, except basal cell carcinoma or squamous cell carcinoma of the skin
Malignancy other than lymphoma, unless (1) in complete remission and more than 5 years from last treatment, or (2) cervical/anal squamous cell carcinoma in situ or (3) superficial basal cell and squamous cell cancers of the skin
History of other malignancies within 5 years prior to day 1 except for tumors that in the opinion of the investigators have a negligible risk for metastasis or death, such as (but not exclusively) adequately controlled basal cell carcinoma, squamous-cell carcinoma of the skin, or early-stage bladder cancer
Have other concurrent malignancy (subjects with treated squamous cell carcinoma of the skin or basal cell carcinoma of the skin may be included), evidence of extrahepatic cancer from their primary malignancy, or ongoing, medically significant active infection.
Subjects with active other tumors, except early stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or cervical intraepithelial neoplasia (CIN)
Concurrent, active malignancies in addition to those being studied (other than cutaneous squamous cell carcinoma or basal cell carcinoma)
No active second malignancy except for basal cell carcinoma of the skin
Active skin lesion consistent with squamous cell carcinoma at the time of randomization, or a current or prior history of malignant melanoma within 5 years of study entry.
Patients with other malignancies diagnosed within 2 years prior to study registration; skin squamous or basal cell carcinoma are exceptions
Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator's opinion will shorten survival to less than 1 year
Concurrent, active malignancies in addition to that being studied (other than cutaneous squamous cell carcinoma or basal cell carcinoma)
Patients with a concurrent active malignancy (except squamous or basal cell carcinoma of the skin)
Concurrent malignancy (excluding basal and squamous cell skin cancers).
treated basal-cell or squamous cell skin carcinoma
Any type of cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or intracerebral metastasis and acute leukemia);
Other current malignancy (except squamous or basal cell skin cancers)
Active second invasive malignancy, other than basal cell carcinoma of the skin.
Patients must be disease-free of prior invasive malignancies for >2 years with the exception of basal cell or squamous cell carcinoma of the skin.
Concurrent active malignancy, with the exception of early stage basal cell or squamous cell skin cancer
Basal cell carcinoma (BCC)
Non-invasive basal cell or squamous cell skin carcinoma.
Previously diagnosed malignancy excluding basal or squamous cell carcinoma of the skin (unless disease-free for 5 years or more)
Malignancy other than lymphoma, unless (1) in complete remission and more than 5 years from last treatment, or (2) cervical/anal squamous cell carcinoma in situ or (3) superficial basal cell and squamous cell cancers of the skin
Patients with a secondary primary cancer (excluding baso/squamous cell carcinoma of skin) within 1 year will be excluded
Patients with second malignancies in addition to multiple myeloma are not eligible if the second malignancy has required treatment within the past 3 years or is not in complete remission; there are two exceptions to this criterion: successfully treated non-metastatic basal cell or squamous cell skin carcinoma
Patients with prior malignancy are eligible; however, the patient must be in remission from the prior malignancy and have completed all chemotherapy and radiotherapy at least 6 months prior to registration and all treatment-related toxicities must have resolved; patients with basal cell or squamous cell carcinoma of the skin are eligible regardless of disease status
No clinical evidence of other malignancies (except basal cell carcinoma)
History of (H/o) another malignancy within 5-years of date of HCT except h/o basal cell or squamous cell carcinoma of skin or PV or ET
Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
Concurrent malignancy (other than squamous cell carcinoma [SCC] or basal cell carcinoma of non-penile skin) that has required surgical or non-surgical treatment in the last 3 years
Basal cell carcinoma of the skin
Squamous cell carcinoma of the skin
Basal or squamous cell carcinoma of the skin
History of other malignancy, with the exception of squamous cell carcinoma of the skin, basal cell carcinoma of the skin, cervical intraepithelial neoplasia, or other malignancies that have been in remission for at least 3 years
Basal cell carcinoma of the skin
Squamous cell carcinoma of the skin
benign basal cell carcinoma
A prior invasive malignant disease within five years except for skin cancer (squamous cell or basal cell carcinoma)
Non-invasive basal cell or squamous cell skin carcinoma.
Invasive cancer other than ovarian cancer within 2 years (except basal or squamous cell carcinoma of the skin that has been definitely treated)
History of other cancer, excluding squamous cell and basal cell skin cancers =< 2 years prior to registration
Other malignancies within the past 3 years except for basal or squamous cell carcinoma of the skin
Curatively treated basal cell/squamous cell skin cancer
Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin
Patients with basal cell carcinoma or squamous cell carcinoma.
Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin
Any additional solid tumour or hematologic malignancy during the past 5 years except T1 skin lesions of squamous cell carcinoma, basal cell carcinoma, or uterine/cervical cancer.
Diagnosis of cancer that in not considered cured, except basal cell carcinoma (BCC) of skin
Basal or squamous cell carcinoma of the skin
Histopathologic diagnosis of basal or squamous cell carcinoma
Patients that have concurrent malignancies (except localized basal cell or squamous cell skin cancers)
Patients who are receiving therapy for another active malignancy are NOT eligible for participation\r\n* The exception to this is squamous cell carcinoma or basal cell carcinoma of the skin
Note: patients with early stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin or cervical intraepithelial neoplasia are eligible for enrollment
Patients with other malignancies diagnosed within 2 years prior to study registration; skin squamous or basal cell carcinoma are exceptions
No concurrent active primary or metastatic cancer other than superficial squamous cell or basal cell skin cancer
Concurrent malignancy (excluding basal and squamous cell skin cancers)
Previous malignant disease (other than target malignancy to be investigated in this trial) within the last 5 years, with the exception of basal or squamous cell carcinoma of the skin.
Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin
Basal cell carcinoma of the skin
Squamous cell carcinoma of the skin
Basal cell carcinoma of the skin
Squamous cell carcinoma of the skin
Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator's opinion will shorten survival to less than 1 year
Previous history of another cancer within 5 years, except completely removed basal or squamous cell skin cancer.
Recent (within 3 years) history of other malignancies, excluding basal cell carcinoma or squamous cell carcinoma of the skin
Have prior history of other malignancies, excluding basal cell carcinoma or squamous cell carcinoma of the skin
Basal cell carcinoma of the skin
Basal cell carcinoma of the skin.
Squamous cell carcinoma of the skin.
Cancer, other than basal-cell or squamous-cell carcinoma of the skin;
Invasive cancer other than ovarian cancer within 2 years (except basal or squamous cell carcinoma of the skin that has been definitely treated)
Non-invasive basal cell or squamous cell skin carcinoma.
An active second primary malignancy with the exception of basal cell or squamous cell skin carcinoma
History of another malignancy within 5-years of date of HCT except history of basal cell or squamous cell carcinoma of skin or PV or ET
Does the patient have a history of prior malignancy, excluding basal or squamous cell carcinoma of the skin, with an expected survival of less than five years?
Any metastatic basal cell carcinoma
history of prior malignancy, excluding basal or squamous cell carcinoma of the skin, with an expected survival of less than 5 years.
History of malignancies other than prostate cancer within the past 5 years, with the exception of treated basal cell/squamous cell carcinoma of the skin
Basal cell carcinoma of the skin
Squamous cell carcinoma of the skin
Evidence of metastatic disease or other malignancy (except squamous or basal cell skin cancers).
Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator’s opinion will shorten survival to less than 1 year
Past history of a cancer diagnosis (excluding basal cell skin carcinoma)
Be free of any recurrence of cancer; and have no other cancers within five years of enrollment except for basal cell or squamous cell tumors of the skin that have been surgically excised
Multiple cancers except basal cell carcinoma
Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin
Diagnosis or recurrence of invasive cancer other than the present cancer within 3 years (except basal or squamous cell carcinoma of the skin that has been definitively treated)
Have not been diagnosed with a prior cancer within the recent 5 years, except basal or squamous cell skin carcinoma
Men with a prior diagnosis of cancer < 5 years ago, excluding basal cell carcinoma and/or squamous cell carcinoma
History of active malignancy, including basal/squamous cell skin cancer
Other co-existing invasive malignancies (with the exclusion of basal cell carcinoma or skin squamous cell carcinoma) diagnosed during the last 2 years before randomization
History of other malignancy =< 2 years prior to the registration/randomization evaluation, with the exception of basal cell or squamous cell skin cancer
History of cancer (excluding basal cell carcinoma of the skin) including cervical cancer
History of other malignancy =< 5 years prior to the registration/randomization evaluation, with the exception of basal cell or squamous cell skin cancer
Basal or squamous cell carcinoma of the skin
Basal cell carcinoma of the skin
Squamous cell carcinoma of the skin
Has active solid tumor malignancies with the exception of localized basal cell or squamous cell skin cancer or the condition under treatment (for example, lymphoma)
Any malignancy within 3 years of baseline; participants with a history of basal cell or squamous cell skin cancer may be enrolled at the discretion of the investigator
Individuals with a history of cancer diagnosis or reoccurrence < 5 years from study entry may not participate; however, individuals with a history of squamous or basal cell carcinoma of the skin < 5 years from study entry will not be excluded from this study
Prior history of any other malignancy within 3 years, other than skin basal cell carcinoma
History of active co-existing non-prostatic malignancies except basal cell skin cancer or squamous cell skin cancer
Active other malignancy (except basal cell or squamous cell skin cancer) within the last 2 years
History of other malignancy (with the exception of squamous cell or basal cell carcinoma of the skin) diagnosed within the last 3 years
Active other malignancy (except basal cell or squamous cell skin cancer) within the last 2 years
Curatively treated basal cell or squamous cell skin cancer
